TEWL Biomarker Study for Diabetic Foot Ulcer Recurrence (TEWL)
Tran-epidermal Water Loss (TEWL) as a Predictive Marker for Diabetic Foot Ulcer (DFU) Recurrence
Sponsor: Indiana University
Listed as NCT04558775, this observational or N/A phase trial focuses on Diabetes and Diabetic and remains completed. Sponsored by Indiana University, it has been updated 10 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Aug 2023 — Jul 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Feb 2023 — Aug 2023 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Apr 2022 — Feb 2023 [monthly]
Recruiting
▶ Show 5 earlier versions
-
Jan 2022 — Apr 2022 [monthly]
Recruiting
-
Dec 2021 — Jan 2022 [monthly]
Recruiting
-
Sep 2021 — Dec 2021 [monthly]
Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Recruiting
-
Oct 2020 — Jan 2021 [monthly]
Recruiting
First recorded
Jun 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Indiana University
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Stanford University
- University of California, San Francisco
- University of Miami
- University of Michigan
- University of Pittsburgh
For direct contact, visit the study record on ClinicalTrials.gov .